Interpace Diagnostics, a unit of PDI, has agreed to acquire Asuragen's miRInform Pancreas and Thyroid cancer tests for $8 million. The deal, which also covers a tissue sample biobank and intellectual property associated with the assays and other thyroid cancer tests under development, should allow Interpace to make inroads in the molecular diagnostics arena.

Related Summaries